Navigation Links
InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
Date:9/17/2009


Optiferrin shown to provide superior performance in cell culture and addresses the need for animal-free transferrin in many applications including Stem Cells, Primary Cells, Hybridoma Cells and Chinese Hamster Ovary (CHO) cells.

Fort Collins, CO September 17, 2009 / b3c newswire / C InVitria today announced the launch of Optiferrin, a high performance, well-defined and animal-free recombinant transferrin for use in mammalian cell culture. Optiferrin is a cell culture supplement which supports cell growth by regulating the amount of iron transported to the cell. Since iron is required for healthy cell culture performance, it is a critical component to reach optimal performance.

Optiferrin has undergone extensive testing by our beta customers since June 2009. They have formulated Optiferrin into their cell culture media to provide maximum performance and they liked their results. We are delighted to be able to bring this sort of value to our customers through innovations like Optiferrin, said Scott Deeter, President & CEO of InVitria.

Transferrin is natures way to deliver iron in a non-toxic manner, said Dr. Steve Pettit, InVitrias Director of Cell Culture Development. Our product development, along with beta customer results, confirmed that Optiferrin delivered optimal performance without any cell damage. This alleviates customers concerns about animal-origin infectious contaminants or the headaches caused by addition of elemental iron and iron chelators in cell culture media, said Dr. Pettit.

Optiferrin is a complimentary product to InVitrias other cell culture supplement products, which include Cellastim, Lacromin, Zap-CHO and Zap-Hybridoma.



About InVitria - www.InVitria.com
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitrias product line, contact us at info@InVitria.com or call 1-800-916-8311.


'/>"/>
b3c newswire

Related biology news :

1. InVitria Sponsors ESACT 2009 in Dublin, Ireland
2. InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO
3. InVitria Announces Launch of Recombinant Albumin for Diagnostics
4. UOG scientists successfully compete for research grants
5. McGill/JGH researchers successfully reverse multiple sclerosis in animals
6. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
7. In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter
8. Salk researchers successfully reprogram keratinocytes attached to a single hair
9. Model successfully predicts large river system fish diversity
10. Scientists successfully treat new mouse model of inflammatory bowel disease
11. Researchers successfully simulate photosynthesis and design a better leaf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)...  IBM (NYSE: IBM ) is introducing several innovative ... to developing collaboration between startups and global businesses, taking place ... the event, nine startups will showcase the solutions they have ... France is one ... a 30 percent increase in the number of startups created ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
Breaking Biology Technology: